Vaccine Effectiveness against Omicron- Pediatric and Adolescent Patients- Monovalent BNT162b2 Vaccine Boosters
Page last reviewed 12 February 2023
Key Points
Key Points are meant to be a scientific, factual summary of the available information that relates solely to the Pfizer-BioNTech COVID-19 Vaccine, as supported by referenced publications within this section. Conclusions should not be drawn from the inclusion or absence of information.
- Vaccine effectiveness (VE) of monovalent BNT162b2 in pediatric and adolescent patients has been studied in Real World Evidence (RWE) studies.(1-13) These studies have noted the benefit of vaccination with a 3rd (booster) dose of monovalent BNT162b2 vaccine against symptomatic COVID-19 infection(9), and Emergency Department (ED)/Urgent Care (UC) visits(2, 13) in adolescents.
- Outcomes of interest, such as symptomatic infection and ED/UC visits, have been studied in recipients of a 3rd (booster) dose of monovalent BNT162b2 (reference group: unvaccinated), in a period of Omicron (B.1.1.529) predominance.(2, 9, 13) VE% (95% CI) against the following outcomes, at the listed times post last vaccine dose, are summarized below. The listed studies cannot be compared due to differences in study design and methodology.
Table Data
Collapse All
Symptomatic infection
| Ages 12-15 years VE %(95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] | Ages 12-17 years VE %(95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] | Ages 16-17 years VE% (95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] |
|---|---|---|
| 2–6.5 weeks: 71 (66–76) (9) | Not reported in studies meeting this website’s inclusion criteria- please refer to Methodology | Not reported in studies meeting this website’s inclusion criteria- please refer to Methodology |
ED/UC visits
| Ages 12-15 years VE %(95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] | Ages 12-17 years VE %(95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] | Ages 16-17 years VE% (95%CI) of 3 doses of BNT162b2 [Reference: Unvaccinated] |
|---|---|---|
| Not reported in studies meeting this website’s inclusion criteria- please refer to Methodology | Median 19 days: 87 (72-94)(13) | ≥ 7 days: 81 (59–91)(2) |
- A 3rd (booster) dose of monovalent BNT162b2 vaccine was observed to provide protection against symptomatic COVID-19 infection(9) and ED/UC visits(2, 13), in children and adolescents aged 12-17 years, in the studies included in this summary.
References: (1) Fowlkes, (2) Klein, (3) Price, (4) Cohen-Stavi, (5) Olson, (6) Lutrick, (7) Oliveira, (8) Reis, (9) Fleming-Dutra, (10) Husin, (11) Sacco, (12) Tan NEJM 2022, (13) Tartof JAMA Netw Open 2022
Publications have reported different definitions of COVID-19 outcomes. Definitions can be found under Primary Endpoints and Definitions for each study below.
